Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTV7XH)

Drug Name
SPN-812 Drug Info
Synonyms
Viloxazine hydrochloride; 35604-67-2; 2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride; Emovit; 2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride; ICI 58,834; Viloxazine hydrochloride [USAN]; 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride; 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, hydrochloride; Vicilan; Vivalan; 2-[(2-ethoxy phenoxy)methyl]morpholine hydrochloride; Morpholine, 2-((2-ethoxyphenoxy)methyl)-, hydrochloride; Viloxazine hydrochloride (USAN); Viloxazine HCl; CCRIS 1915; Viloxacina clorhidrato; ICI-58834; Viloxacina clorhidrato [Spanish]; EINECS 252-638-6; Prestwick_734; 2-((o-Ethoxyphenoxy)methyl)morpholine hydrochloride; Vivalan (TN); 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride; 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine hydrochloride; rac Viloxazine Hydrochloride; DSSTox_CID_31511; DSSTox_RID_97396; DSSTox_GSID_57722; SCHEMBL300741; CHEMBL2106483; DTXSID8057722; Tox21_113955; 1478AE; AKOS015847050; CCG-220828; NCGC00262964-01; CAS-35604-67-2; A6217; FT-0675815; FT-0675816; FT-0675817; FT-0675818; FT-0675819; D02572; Z-1958; 2-(o-ethoxyphenoxymethyl)morpholine hydrochloride; 604E672; SR-01000872636; SR-01000872636-1; W-110863; 2-(2-Ethoxy-phenoxymethyl)-morpholine; hydrochloride; 2-[(2-Ethoxyphenoxy)-methyl]morpholine hydrochloride; Q27285797; 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine hydrochloride
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Phase 4 [1]
Cross-matching ID
PubChem CID
71424
CAS Number
CAS 35604-67-2
TTD Drug ID
DMTV7XH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Norepinephrine transporter (NET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [4]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [5]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [4]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [7]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [8]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [9]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [8]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [10]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [11]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [4]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [5]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [4]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [7]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [8]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [9]
Venlafaxine DMR6QH0 Anxiety disorder 6B00-6B0Z Approved [8]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [10]
Duloxetine DM9BI7M Depression 6A70-6A7Z Approved [11]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [12]
Triflupromazine DMKFQJP Nausea MD90 Approved [13]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [14]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [15]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [16]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [17]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [17]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [17]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [17]
Pyrimidine derivative 27 DMIQSDW N. A. N. A. Patented [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [2]
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT04786990) Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD (ADHD). U.S. National Institutes of Health.
2 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
5 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
6 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
7 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
8 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
9 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
10 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
11 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
12 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
13 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
14 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
15 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
16 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
17 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.